American Brain Foundation’s Cure One, Cure Many Award in Lewy Body Dementia Grant

The American Brain Foundation's Cure One, Cure Many Award in Lewy Body Dementia focuses on advancing research for this underdiagnosed condition. With LBD being the second most common progressive dementia, the foundation seeks innovative applications to discover and validate biomarkers. A grant of up to $2 million over three years is available, encouraging collaboration among diverse research teams to improve diagnosis and treatment options, ultimately aiming for breakthroughs that benefit many.

Since 1992, the American Brain Foundation (ABF) has been investing in research to defeat brain diseases and disorders.
We invest in research of the whole brain and all neurologic disorders knowing they are interconnected. This holistic, innovative approach allows us to build bridges between diseases and break new ground in research and application.
We understand that when we cure one brain disease, we will cure many.
American Brain Foundation’s Cure One, Cure Many Award in Lewy Body Dementia
Lewy body dementia (LBD) is the second most common progressive dementia after Alzheimer’s disease and affects millions of individuals worldwide. When an individual presents with cognitive impairment, however, there are virtually no tools available to enable a clinician to make an accurate diagnosis of LBD. The lack of validated biomarkers for LBD contributes to delayed diagnosis and misdiagnosis, and thus potentially exposes individuals affected by LBD to inappropriate medication use and results in the failure to treat LBD-specific manifestations. The absence of biomarkers also impedes pertinent clinical and translational research, including drug and biomarker discovery efforts.
In collaboration with the American Academy of Neurology (AAN), Alzheimer’s Association, and the Michael J. Fox Foundation for Parkinson’s Research, the 2025 Cure One, Cure Many Award in Lewy Body Dementia now seeks applications aimed for discovery, validation, and acceleration of LBD-related biomarkers. The ABF intends to award a single grant of up to US $2 million for a budget period of up to 3 years. Academic and nonprofit institutions are allowed to allocate up to 15% of the total award amount to indirect costs.

Eligibility

Applications may be submitted by basic, translational, or clinical investigators from:U.S. and international public and private non-profit entities, such as universities, colleges, hospitals, laboratories, units of state and local governments, and eligible agencies of the federal government; andU.S. and international biotechnology/pharmaceutical companies, or other publicly or privately held for-profit entities.Past awardees are eligible to apply for this funding.